Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Slammed bro. Huge slam! Bahahaaa.
KEVETRIN initiated phase 2 around Feb 10th. About 3 months ago. Hoping to hear update soon on cohort 1.
Q: So how does one do that? How can people spot a healthy biotech company, putting aside its stock price?
A: There’s no way to generalize. But you ask: Is the science sound? Is there an unmet need? Has the company built a translational application that is demonstrable in trials? Can you do this at scale? Does the technology improve or impact outcomes for the patient?
Is the science sound; YES
Is there an unmet need: YES
Has the company built a translational application that is demonstrable in trials?: YES
Can you do this at scale?: YES - super YES!!! K and P
Does the technology improve or impact outcomes for the patient? : YES
Greatest Post in highlights. That first highlight is everything CTIX!!!!! Everyone of those questions. CTIX. Yes.
Wow. This made my weekend.
Do you think they may be going for a single buyout? Prove as many indications as possible into mid stages and then sell it all.
Yes. They are trying to maximize the value. They are shareholders just like us. This decline is not fun. However...unlike many other companies....the results on all fronts are looking very good which allows CTIX to be selective and patient...even with the declining share price. As many here have shown: a deal for bio is not linear to current share prices. Especially when there are multiple platforms exceeding expectations. Patience here will absolutely pay off in the 10-100x fashion. There is multiple people in line looking at the same pipeline. Just waiting on data. IMO. It's like the NFL draft. Chicago jumped ahead one spot and gave up a boatload to get their guy. One BP may do the same here shortly. IMO.
This entire FUD fest and takedown has zero to do with ctixs current progress, Aruda nor Aspire on paper.
Last year quarter 1 - 88k in Revs with 18k in cost of Revs. GP - 70k
Let's see what this quarter brings. It will show us a lot imo.
L2 is dancing. Lol. Fun to watch these games and flashes.
Yes. Good point. Plus DF advised they want to be chosen as a future location for the Oral. DF does not say that if they don't see huge potential.
Let's just hope the increase in doses and dosages show some great results.
I think the 10-K said UofB is still interested. Just no funding. All will change in a blink. Huge deal coming this year. And I mean HUGE. Imo
"Based on the accounts of CEOs who believe they
have been the target of naked shorts, here is how the
worst-case scenario might play out using an ill-intentioned
hedge fund (“Fund Malicious”) as an example.
Fund Malicious first identifies a target in the microcap world for
naked shorting, most likely an obscure company in the development
stage or having otherwise questionable fundamentals.
The hedge fund gets that firm listed on a foreign exchange in,
say, Berlin, via a request funneled through a complicit broker
or official in that country. Malicious then sells short shares it
doesn’t have (naked shorts them), waits three days for the DTCC
to call and ask for the shares, and then replies either, “I borrowed
them on the Berlin exchange, and they’ll take some
time to get here,” or “I’m a market-maker for that company’s
shares in Berlin and naked shorting rules don’t apply there.”
The DTCC then loans the fund shares from its
inventory and charges the broker a fee until the
stock loan is repaid. Malicious, in the meantime,
continues to drive the price of the target’s
shares down as long and as aggressively
as possible. In the event the fund does cover
to pay off the stock loan, it doesn’t take much
effort to begin the naked shorting cycle again.
Other theories exist as to how the hedge fund
might skirt additional rules. To prevent “piling
on,” exchange rules mandate that a stock cannot
be shorted on a downtick or decrease in
stock price. In other words, Malicious must wait
for the stock price to increase
briefly before shorting the
company. Rather than wait
passively for an uptick,
though, Fund Malicious can
create an uptick in the stock
itself by purchasing a few
shares through a small offshore
account. The hedge
fund is then free to short (or
naked short) the company
with both barrels at home.
Malicious may get additional leverage out of
the original naked short by choosing to target
an ugly, obscure microcap company. By driving
the price down, the fund hopes to scare existing
shareholders into selling their shares, too, out of
fear that something is going on that they don’t
know about (i.e. the fund can “paint the tape”).
This, of course, drives the price even lower while
further obscuring the role of Fund Malicious.
There is plenty of room for additional mischief
in the above scenario. According to the
most vocal critics of naked shorting, funds like
Malicious have relationships with reporters
and/or message board regulars who are compensated
to distribute negative news about the
company in order to exaggerate the selling.
There is also plenty of irony possible, in that
a CEO can be her shareholders’ worst enemy
by merely uttering the words “naked shorting.”
Investors may panic, the stock might dive further
and legitimate short-sellers could begin to circle."
__________________________________________________
http://www.hawkassociates.com/pdf/uploads/Eat_My_Shorts.pdf
Please disclose who is compensating you for your posts here due to SEC Rule 10 b 5.
CTIX and Science will prevail!
Seriously?
It does apply to every company. But some cannot get there. Seeing the increase in SMS here I think Txhd can. But....time will tell. I'd like to see about 40-50 million texts per month at an avg of .02-.03 per message.
Let's go low end. 40 million at .02 equals $800K
It's very possible. Especially when this platform can do 40 million in a day
I'm newer here and started my DD a couple weeks ago. I'm assuming the CDs from the past brought this down from .10. CDs are a killer. The mms and hedge funds that act as MMS short the heck out of them to gain more shares at a lower point to then cover. I know it's illegal and against all agreements but I know for a fact it happens.
The actual Txhd business and Acquisition of Aspire are all very positive from what I'm finding. They just need to make enough money to run their business and grow organically from here. You can't redo the past and I see they hired a good law firm to look into the BS from the previous CDs. I also see they used cash from last year to pay off a couple CDs. I feel there may be a significant short due to this payoff. Time will tell.
I am hoping for the best and once I see how large some of these Aspire contracts are...I may throw in 10k or more. I think this pps is a steal but I want reassurance.
False. Twilio is failing due to business model relying on a couple major partners. I think uber was like 12% of business? Don't quote me.
Txhd is going after MORE small business and several major business networks. This over time will pay off. Imo.
Txt notifications are the future. School closings, sporting event updates, restaurant reservation updates, specials. Etc...
The short code rates and speed of the new Gen3 holds significant value in the tech sector. Txhd just needs to clean up the CD BS. And restructure the 2 billion into a preferred share for Wais. (If possible)
The Revs and value will come imo.
I suggest buy at the low which is about now. And hold for a year or longer and watch the growth.
Aimo
Good luck
B-UP cohort 3 data would be GLORIOUS before the weekend. It's not in CTIX control but it would be great to go to the DIGESTIVE DISEASE WEEK conference in Chicago this weekend with results in hand. ;)
Great conference
Why the drop?
Real world tech - if Txhd rolls out this new platform that can out perform Twilio and they can prove its scalability and performance. This will be a winner. They just need to be able to pay the bills and stay away from CDs. Keeping the SS as is will be imperative to climb back to all time highs. It will also give the law firm time to stomp on some of these toxic financiers that are short.
I'm watching this company closely.
Good luck all!
My PART II is no joke. It really opens your eyes to how undervalued we are. The progress in 4+ years since 2012 is REMARKABLE. The best is yet to come. IMO.
I am praying P data is superior to Otezla and on par with biologics. :). Maybe a pipe dream.
Remind me the biologics numbers? Let's hypothetically say P delivers your numbers. 75% PASI 75.
What kind of deal would that bring?
Good info. Thanks. Leo and Dr B are on point saying Prurisol overall was very comparable if not better than Otezla at similar stage trials.
This phase 2B will be a defining moment in the CTIX history imo. It will Change all of our lives...and I'm hoping for the better.
Excellent DD. Please remind us of this post come data day. Otezla will be a 2 billion dollar drug almost 3 years into market. If P can outperform. Hello
A partner you will have. GUARANTEED!
Not many shares down here. Low volume. On partner day what could you envision the volume being. Let's say a simple 100-200 million upfront but heavy backloaded deal with extremely CTIX friendly royalties?
10-20-30-40 million share day?
Get your carrots ready.
Some heavy hitters that have been engulfed with real naked shorts who live in Germany have explained things to me that I cannot understand. My brain does not work that way...but it very interesting to hear their stories. Naked shorting and Hedge Funds acting as MMs are all true to the core. The only way we can prove it...is when people go to jail or get fined. There is good literature out there on-the-line proving it is a reality.
I know some true longs hate the topic as it pushes possible new investors away...but everyone should do a little research on Bernard Madoff. One of his famous exceptions was allowing Market Makers to sell short on the downtick, which made it easier for unscrupulous hedge funds to drive down stock prices. This rule was termed the "the madoff exception"
IMO. This stock has been attacked. Read my part II post. The progress and shape of CTIX is 5-10x what it was back in 2012 and we sit below those prices. Aspire has not sold that much to make this difference. Aruda just proved he is not the culprit. All longs I speak to have added significantly over the years.
Yet........there are libelous articles and slanderous posts on message boards over the years that drive this down. All proven to be 100% FALSE! In a court of law. So for one to tell me there is no naked short or illegal happenings here...BS.
The Good news. One deal of epic proportion and or buyout really burns those that refuse to cover. BK and jail time for those organizations imo. This pipeline cannot be held down forever. BP needs new drugs.
Bravo! Your description is point on. Especially the correction
Let's hear that again for these Ovarian resistant patients. I am hopeful that K will allow the body to get back to what e body is meant to do.
Never forget about K as well. To hear safety news and moving to cohort 2 would be great. Dosing 3 times a week at 250 mg/m2 to start is so much more than phase 1.
Maybe we can hope K shrinks the tumors in 3 weeks?
If data and indications continue to pile up in a positive light. Yes. I believe B to be well above some of the last couple years major deals. I know you are extremely light on your position here so keep acting tough and we will see you again when ur bloated to the to the gills - screaming positive things.
We know you have stated. Phase 3 is a lock for absssi. That indication alone can produce yearly revs over a billion IMO.
Add OM, add several Gastro indications - billion(s), acne, HP, etc. topical application to implants. I can say yearly revs could exceed several billions.
Time will tell but I have many behind me with the same calculations.
No one here can prove the CTIX pipeline is failing. On the contrary. Every drug that CTIX has taken into human trials is proving to be safe and effective. The safety profiles have been amazing. The manufacturing has been proven to be better than the competition. So far the efficacy has been on par with competitors.
Leo has a plan. We all need not worry. It's the old shuffle those feet and keep dancing....take punches but keep hands up. When least expected BAM! The giant will be tired and CTIX will deliver the final blow!
I truly believe. Really unbelievable things are being discussed and will be delivered when least expected.
Briacidin is proving to be a cash cow. Past deals of 7-9 billion are low for what B can offer. IMO. We just need great data.
Agree. It will be interesting to see the higher dose numbers on moderate to severe. I assume the numbers should look a lot better than the phase 2 lower dose on mild-moderate. Especially using that scale - must be greater than 2 point reduction.
Mild to moderate treatment is where the big money will come in though. Especially if P can prove less side effects as an oral and better efficacy.
Jmo
I'd have to go back. But I think BK posted once about the truth behind Aruda and his "real" knowledge of Kevetrin. It was interesting but I can't remember off top of head.
Either way. The filing today can SLAP us all in the face with how brutal this place is and how ridiculous some sound and now proven by facts and sec documents. As Leo said: please stick to company released PRs and sec documents for facts. There is a huge black vail being casted over CTIX by people that are trying to benefit from the negative light.
If we all stick to facts. It is CLEAR! This company is doing unbelievable things in a positive way!
Did you see Aruda's VOLUNTARY filing today? Looks like he has slowed from an average of 180k plus a month to only 30K a month. WOW
SO IF ITS NOT ARUDA? And it's not ASPIRE? Who could it be???? Lol
CTIX will reconnect with true value soon! 5-10x where we are now! IMO.
The only negative item is we added almost 40Million to OS in 4+ years.
That is the ONLY NEGATIVE!!! But when you factor the progress of adding 10 compounds, 3 HUGE MGMT names, completing 4 clinical trials (all successfully) starting 4 other clinical trials in progress, defending the company using shares to pay Ashcroft who won the trial and was dismissed with prejudice, additional pre-clinical studies on K - Oral, B for IL-17 (acne, Hidradenitis Suppurativa, Chrohn's Disease, Atopic Dermatitis, Eye and Ear, Diabetic Foot and Ulcer, B-Foam, etc.........
I can go on - so only adding 40 million to OS over 4+ years to accomplish all of the above and so much more.... Seems like a garage sale style frugal spending to me.
GREAT JOB LEO!!!!!
I STRESS: ADDED - 70 MILLION PLUS IN FINANCING/CASH AVAILABLE, ADDED 5 FDA DESIGNATION, ADDED 3 HUGE NAMES TO MGMT, ADDED 8 CLINICAL TRIALS (COMPLETED 4 SUCCESSFULLY - 4 IN PROGRESS), ADDED 10 COMPOUNDS INCLUDING PATENTS.....
And the share price is back to where it was when CTIX had ZERO of the above. ZERO of the ABOVE... LOL - I would say we should be 5 - 10X where the current share price is.
BOOM - GO CTIX
PART II *** Please Read
A comparison to PART I which was when the share price was around .65 - 1.00 back in summer of 2012. This PART II will give brief facts compared to PART I (4+ Year difference)
April 27th 2017 - Share closed at .7199
Cash on Hand from 10-Q ending Dec 31st 2016 - 3.9 Million (Plus the 2.2 Million from the 3/31 PIPE) so about 6.1 Million (COMPARE THAT TO $27,000 Cash on hand in 2012)
FINANCING AVAILABLE: Approx $19 Million from Aspire was available per 10-Q as of Dec 31st 2016 (In 2012 there was no funding available at the time the share price was the same as today)
SHELF REG: $45 million available under the Company’s effective shelf registration statement. This was filed March 31st 2015 (WAS NOT AVAIL in 2012)
CURRENT OS: January 27, 2017 -
126,408,756
Add the PIPE of 2,471,912 - so Approx - 129 Million OS (Compared to approx 93 MILLION SEPT 30th 2012)
CLINICAL TRIALS: (Daubs summary)
1) PHASE I: A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
(Start: Oct 2012 - End: Feb 2016) SUCCESSFUL
2) PHASE 2B: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
(Start: Feb 2014 - END: Oct 2014) SUCCESSFUL
***Compared favorably to Daptomycin which is a blockbuster drug
3) PHASE I: Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers
(Start: March 2014 - End: Oct 2014) SUCCESFUL
4) PHASE II: Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis
(Start: Aug 2015 - End: May 2016) SUCCESSFUL
5) PHASE 2B: Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
(Start: Oct 2016 - End: IN PROGRESS Estimated July 2017)
6) PHASE 2: Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer (Brilacidin)
(Start: May 2015 - End: IN PROGRESS Estimated Dec 2017)
Interim Data - Patients swishing B 3x a day developed Sever OM 22.2% compared to the Placebo arm that developed severe OM 70% (THERE IS NO CURRENT SOC FOR PREVENTING OM)
7) A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
(Start: Feb 2017 - End: IN PROGRESS Estimated Dec 2017)
8) A Phase 2 open label Proof-of-Concept trial evaluating Brilacidin as a new treatment for mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease
(Start: June 2016 - End: IN PROGRESS Estimated 1H 2017) (weeks)
The share price in Aug-Sept 2012 was above current share price and there were ZERO clinical trials at that point. AGAIN LOOK ABOVE AT WAS HAS BEEN COMPLETED SINCE THEN
DESIGNATIONS FROM THE FDA:
Brilacidin -
1) QIDP Fast Track Designation ABSSSI - Dec 2014
2) Fast track Designation for OM - Nov 2015 (The company just released if the final OM results are on par with interim they will apply for BREAKTHROUGH DESIGNATION)
KEVETRIN -
3) Orphan Drug Designation for Ovarian Cancer - July 2015
4) Orphan Drug Designation for Retinoblastoma - Nov 2015
5) Rare Pediatric Disease Designation for Retinoblastoma - Nov 2015
(the case for Silver Spring-based United Therapeutics Corp., which sold a voucher for $350 million in 2015)
*Orphan Drug Designation for Pancreatic Cancer - Jan 2016
The only FDA designation that CTIX had in 2012 when the share price was between .60-1.00 was from June 2012 for Prurisol - 505 (b)(2) Approach
CURRENT PIPELINE IMAGE:
https://static1.squarespace.com/static/5715352e20c647639137f992/t/5835f4b020099ed326eed244/1479931063630/?format=1500w
ADDITIONAL HIRES:
Dr. Arthur P. Bertolino - President and CMO
LaVonne Lang - VP Regulatory Affairs
Jane Harness - VP Clinical Sciences
COMPOUNDS OWNED BY CTIX in 2012: 8 TOTAL
Kevetrin
KM 133
KM 391
KM 277
KM 278
KM 362
KM-3174
KM-732
ADDITIONAL COMPOUNDS OWNED AFTER POLYMEDIX's acquisition: 18 TOTAL
**THIS INCLUDES PATENTS** It also included "SUBSTANTIAL EQUIPMENT ASSETS"
"We are very excited about instantly having a strong antibiotic franchise to complement our already robust pipeline that now contains 18 compounds"
SO AGAIN MY FRIENDS!!! We are sitting at or below the share price in 2012 where, yes we have added about 40 million to the OS - BUT does that increase really justify the share price to stay the same as we note the progress that has been made over those 4+ years? GET READY FOR A CORRECTION SOON!!! GO CTIX!!!!
PART I *** PLEASE READ
As I promised I wanted to show iHub readers the last time CTIX was near the current .71 price range. You would have to go WAY back - and I mean WAY back to 2012.
AUGUST 31st 2012 - Closed at .63
September 31st 2012 - Closed at 1.00
In the 10-K released on 10/12/12 I found the below info. Here is link to 10-K (https://www.bamsec.com/filing/154823312000017?cik=1355250)
CASH ON HAND - $27,000
CTIX did not have any major Stock Purchase Agreements at the time! So no funds readily available.
OS as of SEPT 30th 2012 - - 93,124,151 (ONLY 33 MILLION LESS than now)
They had ZERO ongoing CLINICAL trials - just pre-clinical work.
Some notes of accomplishments though:
Jan 2012 - Prurisol Patent Filed
March 2012 - BIDMC Agreement to test Keveterin
May 2012 - Jim Boeheim joined as advisor (lol) Jim is a good man but this was exciting at the time.
June 2012 - IND Meeting with FDA approved to seek section 505(b)(2)
June 2012 - IND approved by FDA to begin Phase 1 trial at Dana Farber and BIDMC for Keveterin
Sept 2012 - Selected Dr. Reddy's Lab to manufacturer P
CTIX owned 8 compounds
________________________________________________________________
Now someone else can start PART II if they want or I can do it tomorrow comparing that above to where we are currently today. It is going to be MIND BLOWING! that we are at .71 - like I am actually so confused as I just looked up this info on how the heck we sit at .71 I may go start drinking. And I have to be up and get a good session in at the gym in 4 hours before I start my busy work week...
Job well done Leo - I must say - to only add 30+ million shares over 5 years and to accomplish what my Part II will discuss... BRAVO!!!
Goodnight CTIXer's
AND YOU CARE WHY? What...did you pick up shares again
My Fellow Shareholder,
...The article struck a chord with me, as it lends some color to how certain characters leverage anonymity on the Internet to smear the good name of others only in an attempt to benefit themselves.
...I share this with all of you because it exemplifies that dark side of the Internet and the lengths that some bad actors will go to. It also proves that with persistent effort and the right resources that those individuals can be identified, no matter how cleverly they believe they have covered their tracks.
We assured you that the lawsuit by the Rosen Law Firm was frivolous. The court agreed. We didn’t stop there. You can believe me that our team is on top of bringing the culprits behind the attack on Cellceutix to justice.
We encourage current and future CTIX shareholders to rely only upon credible sources, including our news releases, research data and filings with the Securities and Exchange Commission. To that point, I am pleased to say that as of this morning we are still on target to provide an efficacy report this week from the second cohort in the open label Phase 2 trial of Brilacidin for ulcerative colitis. We also are looking forward in the coming weeks to releasing an interim analysis of data from the double-blind Phase 2 study of Brilacidin-OM for the prevention and treatment of oral mucositis.
These are truly exciting times at Cellceutix and I thank you for the ongoing support.
All the best,
Leo
Was that patent April 4th?
I can't imagine but also can't wait!!